替格瑞洛轻度升高健康人血浆核黄素并抑制BCRP与MRP4转运
该研究在同一项药物相互作用试验中,评估90 mg替格瑞洛对健康志愿者血浆核黄素浓度的影响。替格瑞洛使核黄素峰浓度与给药前空腹浓度比值较安慰剂升高1.20倍(90%CI 1.10-1.32;P=0.006)。体外实验显示核黄素经BCRP和MRP4转运,替格瑞洛抑制二者的未结合50%抑制浓度分别为0.020 μM和1.1 μM。
要点
- 替格瑞洛使血浆核黄素峰/空腹浓度比值较安慰剂升高1.20倍(90%CI 1.10-1.32)。
- 核黄素经BCRP和MRP4转运,替格瑞洛对二者的未结合IC50为0.020 μM和1.1 μM。
- 肠道MRP4可促进核黄素吸收,可能限制其作为肠道BCRP生物标志物的效用。
核心结论
- 替格瑞洛轻度升高健康人血浆核黄素浓度,可能主要通过抑制肠道BCRP实现。
研究设计与样本
- 在同一项健康志愿者药物相互作用研究中,比较90 mg替格瑞洛与安慰剂对血浆核黄素浓度的影响,并开展体外转运实验。
主要发现
- 替格瑞洛使核黄素峰浓度与给药前空腹浓度比值较安慰剂升高1.20倍(90%CI 1.10-1.32;P=0.006)。
- 体外核黄素经BCRP和MRP4转运,未观察到MRP2、MRP3或P-糖蛋白的明显转运。
- 替格瑞洛抑制BCRP和MRP4转运核黄素的未结合50%抑制浓度分别为0.020 μM和1.1 μM。
- 基于囊泡和组织蛋白表达数据估算,小肠MRP4介导的核黄素外排清除率(1.2-1.4 nL/min/mg)与BCRP介导的(0.23-1.3 nL/min/mg)相近。
临床怎么用
- 临床解读核黄素作为肠道BCRP生物标志物时,需考虑替格瑞洛等BCRP抑制剂的影响。
- 肠道MRP4对核黄素吸收的贡献可能削弱核黄素反映肠道BCRP活性的特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Riboflavin (vitamin B2) has been proposed as a biomarker for breast cancer resistance protein (BCRP) activity. In recent studies in mice, cynomolgus monkeys, and humans, BCRP-inhibiting drugs increased the plasma concentration of riboflavin. We showed recently that ticagrelor inhibits BCRP and raises the plasma concentrations of the BCRP substrate rosuvastatin in healthy volunteers. In the same drug-drug interaction study, we now investigated whether ticagrelor affects the plasma concentrations of riboflavin. Intake of 90 mg ticagrelor increased the ratio between the peak plasma riboflavin concentration and the fasting riboflavin concentration before ticagrelor administration by 1.20-fold (90% confidence interval, 1.10-1.32; P = 0.006) compared to placebo. In vitro, riboflavin was transported by BCRP and multidrug-resistance-associated protein 4 (MRP4) but no clear transport was observed by MRP2, MRP3, or the P-glycoprotein. Moreover, ticagrelor inhibited the transport of riboflavin in BCRP- and MRP4-expressing membrane vesicles with unbound 50% inhibitory concentrations of 0.020 and 1.1 μM, respectively. Based on vesicle and tissue protein expression data, the small intestinal MRP4-mediated efflux clearance of riboflavin (1.2-1.4 nL/min/mg) was estimated to be similar to that mediated by BCRP (0.23-1.3 nL/min/mg). As MRP4 is expressed in the basolateral membrane of enterocytes, it may facilitate the absorption of riboflavin and impair the utility of riboflavin as a biomarker of intestinal BCRP. To conclude, ticagrelor modestly raises the plasma concentration of riboflavin probably by inhibiting intestinal BCRP. Inhibition of intestinal MRP4 may have reduced the absorption of riboflavin and limited the effect of ticagrelor on riboflavin levels.
引用
- Deng F, Hämäläinen K, Lehtisalo M, et al. Ticagrelor modestly raises plasma riboflavin concentration in humans and inhibits riboflavin transport by BCRP and MRP4. Clin Pharmacol Ther. 2024. PMID: 39039844. doi:10.1002/cpt.3384
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。